Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine

Kathleen M. Daddario-DiCaprio, Thomas Geisbert, Joan B. Geisbert, Ute Ströher, Lisa E. Hensley, Allen Grolla, Elizabeth A. Fritz, Friederike Feldmann, Heinz Feldmann, Steven M. Jones

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in infected patients. MARV is also considered to have potential as a biological weapon. Recently, we reported the development of a promising attenuated, replication-competent vaccine against MARV based on recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of the Musoke strain of MARV (VSVAG/MARV GP-Musoke). We used this vaccine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge. While these results are highly encouraging, an effective vaccine would need to confer protection against all relevant strains of MARV. Here, we evaluated the protective efficacy of the VSVAG/MARVGP-Musoke vaccine against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain. In this study, seven cynomolgus monkeys were vaccinated with the VSVAG/MARVGP-Musoke vector. Three of these animals were challenged with the Angola strain, three with the Ravn strain, and a single animal with the Musoke strain of MARV. Two animals served as controls and were each injected with a nonspecific VSV vector; these controls were challenged with the Angola and Ravn strains, respectively. Both controls succumbed to challenge by day 8. However, none of the specifically vaccinated animals showed any evidence of illness either from the vaccination or from the MARV challenges and all of these animals survived. These data suggest that the VSVAG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains.

Original languageEnglish (US)
Pages (from-to)9659-9666
Number of pages8
JournalJournal of Virology
Volume80
Issue number19
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Marburg virus
Marburgvirus
Cross Protection
Attenuated Vaccines
Synthetic Vaccines
live vaccines
recombinant vaccines
Angola
Vaccines
vaccines
Vesiculovirus
Vesicular Stomatitis
Macaca fascicularis
animals
Biological Warfare Agents
Viruses

ASJC Scopus subject areas

  • Immunology

Cite this

Daddario-DiCaprio, K. M., Geisbert, T., Geisbert, J. B., Ströher, U., Hensley, L. E., Grolla, A., ... Jones, S. M. (2006). Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. Journal of Virology, 80(19), 9659-9666. https://doi.org/10.1128/JVI.00959-06

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. / Daddario-DiCaprio, Kathleen M.; Geisbert, Thomas; Geisbert, Joan B.; Ströher, Ute; Hensley, Lisa E.; Grolla, Allen; Fritz, Elizabeth A.; Feldmann, Friederike; Feldmann, Heinz; Jones, Steven M.

In: Journal of Virology, Vol. 80, No. 19, 10.2006, p. 9659-9666.

Research output: Contribution to journalArticle

Daddario-DiCaprio, KM, Geisbert, T, Geisbert, JB, Ströher, U, Hensley, LE, Grolla, A, Fritz, EA, Feldmann, F, Feldmann, H & Jones, SM 2006, 'Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine', Journal of Virology, vol. 80, no. 19, pp. 9659-9666. https://doi.org/10.1128/JVI.00959-06
Daddario-DiCaprio, Kathleen M. ; Geisbert, Thomas ; Geisbert, Joan B. ; Ströher, Ute ; Hensley, Lisa E. ; Grolla, Allen ; Fritz, Elizabeth A. ; Feldmann, Friederike ; Feldmann, Heinz ; Jones, Steven M. / Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. In: Journal of Virology. 2006 ; Vol. 80, No. 19. pp. 9659-9666.
@article{749ac0726c4e44268010cbe57af1649e,
title = "Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine",
abstract = "Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in infected patients. MARV is also considered to have potential as a biological weapon. Recently, we reported the development of a promising attenuated, replication-competent vaccine against MARV based on recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of the Musoke strain of MARV (VSVAG/MARV GP-Musoke). We used this vaccine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge. While these results are highly encouraging, an effective vaccine would need to confer protection against all relevant strains of MARV. Here, we evaluated the protective efficacy of the VSVAG/MARVGP-Musoke vaccine against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain. In this study, seven cynomolgus monkeys were vaccinated with the VSVAG/MARVGP-Musoke vector. Three of these animals were challenged with the Angola strain, three with the Ravn strain, and a single animal with the Musoke strain of MARV. Two animals served as controls and were each injected with a nonspecific VSV vector; these controls were challenged with the Angola and Ravn strains, respectively. Both controls succumbed to challenge by day 8. However, none of the specifically vaccinated animals showed any evidence of illness either from the vaccination or from the MARV challenges and all of these animals survived. These data suggest that the VSVAG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains.",
author = "Daddario-DiCaprio, {Kathleen M.} and Thomas Geisbert and Geisbert, {Joan B.} and Ute Str{\"o}her and Hensley, {Lisa E.} and Allen Grolla and Fritz, {Elizabeth A.} and Friederike Feldmann and Heinz Feldmann and Jones, {Steven M.}",
year = "2006",
month = "10",
doi = "10.1128/JVI.00959-06",
language = "English (US)",
volume = "80",
pages = "9659--9666",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "19",

}

TY - JOUR

T1 - Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine

AU - Daddario-DiCaprio, Kathleen M.

AU - Geisbert, Thomas

AU - Geisbert, Joan B.

AU - Ströher, Ute

AU - Hensley, Lisa E.

AU - Grolla, Allen

AU - Fritz, Elizabeth A.

AU - Feldmann, Friederike

AU - Feldmann, Heinz

AU - Jones, Steven M.

PY - 2006/10

Y1 - 2006/10

N2 - Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in infected patients. MARV is also considered to have potential as a biological weapon. Recently, we reported the development of a promising attenuated, replication-competent vaccine against MARV based on recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of the Musoke strain of MARV (VSVAG/MARV GP-Musoke). We used this vaccine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge. While these results are highly encouraging, an effective vaccine would need to confer protection against all relevant strains of MARV. Here, we evaluated the protective efficacy of the VSVAG/MARVGP-Musoke vaccine against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain. In this study, seven cynomolgus monkeys were vaccinated with the VSVAG/MARVGP-Musoke vector. Three of these animals were challenged with the Angola strain, three with the Ravn strain, and a single animal with the Musoke strain of MARV. Two animals served as controls and were each injected with a nonspecific VSV vector; these controls were challenged with the Angola and Ravn strains, respectively. Both controls succumbed to challenge by day 8. However, none of the specifically vaccinated animals showed any evidence of illness either from the vaccination or from the MARV challenges and all of these animals survived. These data suggest that the VSVAG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains.

AB - Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in infected patients. MARV is also considered to have potential as a biological weapon. Recently, we reported the development of a promising attenuated, replication-competent vaccine against MARV based on recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of the Musoke strain of MARV (VSVAG/MARV GP-Musoke). We used this vaccine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge. While these results are highly encouraging, an effective vaccine would need to confer protection against all relevant strains of MARV. Here, we evaluated the protective efficacy of the VSVAG/MARVGP-Musoke vaccine against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain. In this study, seven cynomolgus monkeys were vaccinated with the VSVAG/MARVGP-Musoke vector. Three of these animals were challenged with the Angola strain, three with the Ravn strain, and a single animal with the Musoke strain of MARV. Two animals served as controls and were each injected with a nonspecific VSV vector; these controls were challenged with the Angola and Ravn strains, respectively. Both controls succumbed to challenge by day 8. However, none of the specifically vaccinated animals showed any evidence of illness either from the vaccination or from the MARV challenges and all of these animals survived. These data suggest that the VSVAG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains.

UR - http://www.scopus.com/inward/record.url?scp=33748929005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748929005&partnerID=8YFLogxK

U2 - 10.1128/JVI.00959-06

DO - 10.1128/JVI.00959-06

M3 - Article

VL - 80

SP - 9659

EP - 9666

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 19

ER -